Back to News
Market Impact: 0.35
Humacyte's ATEV Shows Phase 3 Benefits In Women, Supports Planned FDA Label Expansion
Source: Nasdaq
Healthcare & Biotech
Humacyte reported positive interim results from its Phase 3 V012 trial of its investigational acellular tissue engineered vessel (ATEV) versus AV fistula for hemodialysis access in female patients with end-stage kidney disease. The announcement provides no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
HUMA0.70
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Cumberland Pharmaceuticals stock tumbles on trial results